Skip to main content


We're creating a new version of this page. See preview

  • Poster presentation
  • Open Access

Remarkable improvement of articular pain by biologics in a Multicentric carpotarsal osteolysis patient with a mutation of MAFB gene.

  • 1,
  • 1,
  • 2,
  • 1,
  • 1,
  • 1,
  • 3 and
  • 1
Pediatric Rheumatology201513 (Suppl 1) :P152

  • Published:


  • Infliximab
  • Juvenile Idiopathic Arthritis
  • Tocilizumab
  • Heterozygous Mutation
  • Remarkable Improvement


Multicentric carpotarsal osteolysis syndrome (MCTO) is a rare autosomal dominant disorder, characterized by aggressive osteolysis of the carpal and tarsal bone, and progressive nephropathy leading to end-stage renal disease. Recently, heterozygous mutations in MAFB gene within a short region of the amino-terminal transcriptional activation domain had been reported to cause MCTO. Although affected patients suffer from early childhood with a clinical appearance mimicking juvenile idiopathic arthritis, most of anti-rheumatic agents are ineffective to control their pain.

Patients and methods

A fifteen year old boy was born to healthy parents. There was no family history of consanguinity, skeletal disorders, and rheumatic disorders. He was well until 26 months of age, when he showed claudication symptoms. He was referred for painful and swollen feet, wrists and pes cavus. He also had craniofacial abnormalities of micrognathia, hypotelorism, chubby cheeks and flat face. He showed gradual progression of osteolysis predominantly in the carpal and tarsal bones, and progressive nephropathy with hematoproteinuria. Whole exome sequencing analysis detected a de novo heterozygous mutation in MAFB gene which was confirmed by Sanger sequencing. Because this mutation had been reported as a responsible mutation of MCTO, we diagnosed the patient as MCTO caused by the mutation. Until this point, he was treated as a relative disease of juvenile idiopathic arthritis with non-steroidal anti-inflammatory agents, methotrexate, which was not effective to relieve not only osteolysis but articular pain of the patient. At the age of five, he was started to treat with intravenous infliximab by which pain decreased and eventually disappeared in a mean time. Proggressive osteolysis of the carpal and tarsal bone continued and the deformity of fingers was evolved. Therefore, at the age of eight, his biologics was changed to intravenous tocilizumab every 6 weeks. After 3 months treatment, the pain and tenderness in his wrists and fingers disappeared.


Intravenous tocilizumab every 6 weeks, resulted in remarkable improvement of his articular pain, although osteolysis of the patient remained progressing. The patient became free to pain and could do personal care without difficulty.


Tocilizumab could be an effective therapy for relief of articular pain of MCTO.

Consent to publish

Written informated consent for publication of their clinical details was obtained from the patient/parent/guardian/relative of the patient.

Authors’ Affiliations

Department of Pediatrics, Kyoto University Graduate School of Medicine, Kyoto, Japan
Department of Pediatrics, Aichi Medical University, Nagakute, Japan
Department of Human Genome Research, Kazusa DNA Research Institute, Chiba, Japan


© Nishikomoti et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.